HomeCompareBIOAF vs EPRT

BIOAF vs EPRT: Dividend Comparison 2026

BIOAF yields 1000000.00% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOAF wins by $4.7683925249533696e+36M in total portfolio value
10 years
BIOAF
BIOAF
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full BIOAF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — BIOAF vs EPRT

📍 BIOAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOAFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOAF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOAF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOAF
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, BIOAF beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOAF + EPRT for your $10,000?

BIOAF: 50%EPRT: 50%
100% EPRT50/50100% BIOAF
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

BIOAF
No analyst data
Altman Z
-42.0
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOAF buys
0
EPRT buys
0
No recent congressional trades found for BIOAF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOAFEPRT
Forward yield1000000.00%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$4.7683925249533696e+36M$63.4K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$12,840.73
Total dividends collected$4.7683311610149396e+36M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BIOAF vs EPRT ($10,000, DRIP)

YearBIOAF PortfolioBIOAF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,205$505.18+$100.00MBIOAF
2$934,786,450,701$934,679,439,252.34$12,672$682.46+$934786.44MBIOAF
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,490$930.48+$8165787108.56MBIOAF
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,786$1,282.69+$66665884190957.63MBIOAF
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$19,753$1,791.56+$508662171058048128.00MBIOAF
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$23,677$2,541.64+$3.62723524842849e+21MBIOAF
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$29,008$3,672.99+$2.417368115915061e+25MBIOAF
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$36,463$5,425.08+$1.5056740286145463e+29MBIOAF
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$47,238$8,221.57+$8.764771002818475e+32MBIOAF
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$63,385$12,840.73+$4.7683925249533696e+36MBIOAF

BIOAF vs EPRT: Complete Analysis 2026

BIOAFStock

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Full BIOAF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this BIOAF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOAF vs SCHDBIOAF vs JEPIBIOAF vs OBIOAF vs KOBIOAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.